Absci appoints Ransi Somaratne as CMO; Chief Innovation Officer Andreas Busch to retire

Absci Corp

Ransi Somaratne, formerly SVP Clinical Development at Vertex, appointed CMO effective March 3, 2026.
Andreas Busch, Chief Innovation Officer, will retire March 31, 2026 and serve as scientific advisor for 2 years.
Busch receives $25,500 annual retainer plus grants of 22,800 stock options and 5,800 RSUs under the 2021 Plan.
Busch's vested options (2,489,290 shares) extended up to 3 months post-advisory termination; unvested options cancelled.
Amended director and officer indemnification agreements adopted March 6, 2026, enhancing change-in-control and good faith provisions.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.